
perceptive imaging

Advancing Solid Tumor Development with Confidence



Perceptive is a leading imaging core lab for solid tumor clinical trials, having supported over 1,800 studies and more than 270 regulatory approvals to date.

Whether your study involves RECIST, PCWG4, RANO or other oncology imaging endpoints, radioligand therapies, or complex clinical biomarker integration, our scalable oncology imaging services deliver the expertise and infrastructure needed to meet the highest data standards and regulatory rigor.

Solid Tumor Trial Imaging Expertise

We have supported all phases of solid tumor clinical development and have helped sponsors meet global regulatory expectations across both standard-of-care and advanced medical imaging. Our expertise includes, but is not limited to:

INDICATIONS	RESPONSE CRITERIA	MOLECULE TYPES	MODALITIES	ADVANCED IMAGE ANALYSIS
Lung Cancer	RECIST 1.1	Small molecules	CT	Radiomics
Breast Cancer	iRECIST	Radioligand therapies	MRI	Dosimetry
Colorectal Cancer	iRC	Proteins incl. ADCs	X-ray	Automated PSMA Segmentation
Prostate Cancer	mRECIST	Gene therapies	Bone Scan	
HCC	PERCIST	Cell therapies	PET	
Melanoma	PCWG3/PCWG4	Peptides	SPECT	
Ovarian Cancer	RANO variants	Vaccines	Mammography	
RCC		RNA-based therapies	Photography	
Primary Brain Tumors				

Clinical Radiopharmaceutical Services

Perceptive is the industry's most experienced imaging partner in radioligand / radiopharmaceutical therapy (RPT), supporting over 100 clinical trials and 6 approvals, as well as thousands of preclinical programs across a wide range of targets and tumor types.

We support the full lifecycle of theranostics and radioligand therapy trials — ensuring patient safety from early-phase dose optimization and biodistribution through global Phase III execution.

The Faster Path for RECIST 1.1 Start-up

RECIST 1.1 underpins the vast majority of solid tumor trials, yet significant time is spent building study charters, as well as configuring and validating read workflows. Our core RECIST 1.1 solution applies the criteria exactly as written, using pre-validated medical logic and standardized, production-ready workflows. This enables trials to be 'read-ready' in days instead of the typical weeks required for custom configuration. Most trials fit a standardized RECIST 1.1 approach, with custom options available when protocols require flexibility.

Scientific Leadership

Perceptive Imaging brings together clinical, scientific, and medical imaging experts who have helped shape development strategies within sponsor organizations, alongside operational teams with deep expertise in executing complex imaging programs. We understand what you need to achieve, anticipate the challenges that may stand in the way, and translate that understanding into consistent execution, high quality data, and imaging evidence you can trust.



Gregory Goldmacher MD, PhD, MBA
Chief Scientific & Medical Officer



Manish Sharma, MD
Chief Medical Officer, Oncology



Oliver Bohnsack MD, PhD, MBA
Vice President, Scientific and Medical Services



Peter Eggleton, MD, FFPM
Vice President, Scientific & Medical Services

How can we help?

Advance your solid tumor trial with confidence. Contact:

hello@perceptive.com

©2026 Perceptive

perceptive imaging